For adult patients with CML failing on one 2G TKI, ICLUSIG®
combines experience and data to improve their futures1–3*
Ph+ CML
ICLUSIG is indicated in adult patients suffering from T315I-positive Philadephia-positive (Ph+) chronic
myeloid leukemia (chronic phase, accelerated phase, or blast phase), or Ph+ chronic myeloid leukemia
(chronic phase, accelerated phase or blast phase) for whom a treatment with other c-abl tyrosine kinase
inhibitors is not appropriate.1
Also available
for your
patients with Ph+ ALL
Ph+ ALL
ICLUSIG is indicated in adult patients suffering from T315I-positive Ph+ acute lymphoblastic
leukemia, or Ph+ acute lymphoblastic leukemia for whom a treatment with other c-abl tyrosine kinase
inhibitors is not appropriate.1
You are now leaving the site www.iclusig.ch.
This link will take you to a site https://www.incyte.com, owned by Incyte Corporation and managed
by the company.